← Back to Screener
CytoMed Therapeutics Limited Ordinary Shares (GDTC)
Price$1.29
Growth ScoreA
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-37.82%
Price vs S&P 500 (4W)65.39%
VGM Score73.59
Market Capitalization$11.87M
All Metrics
Book Value / Share (Quarterly)$0.43
P/TBV (Annual)3.15x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.29
Price vs S&P 500 (YTD)-11.53%
EPS (TTM)$-0.27
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-0.27
EPS (Annual)$-0.27
ROI (Annual)-56.65%
Gross Margin (Annual)95.22%
Cash / Share (Quarterly)$0.14
Revenue Growth QoQ (YoY)142.45%
ROA (Last FY)-49.85%
Revenue Growth TTM (YoY)366.75%
EBITD / Share (TTM)$-0.24
ROE (5Y Avg)-147.06%
Cash Flow / Share (Annual)$-0.29
P/B Ratio3.01x
P/B Ratio (Quarterly)3.09x
Net Income / Employee (Annual)$-73,700
Net Interest Coverage (TTM)-16.12x
ROA (TTM)-48.71%
EPS Incl Extra (Annual)$-0.27
Current Ratio (Annual)5.17x
Quick Ratio (Quarterly)3.18x
3-Month Avg Trading Volume0.40M
52-Week Price Return-36.14%
Revenue / Employee (TTM)$5,986
Tangible BV / Share (Quarterly)$0.42
P/S Ratio (Annual)60.74x
Asset Turnover (Annual)0.04x
52-Week High$3.68
EPS Excl Extra (Annual)$-0.27
CapEx CAGR (5Y)21.10%
26-Week Price Return-29.89%
Quick Ratio (Annual)3.18x
13-Week Price Return24.04%
Total Debt / Equity (Annual)0.07x
Current Ratio (Quarterly)5.17x
Enterprise Value$14.06M
Revenue / Employee (Annual)$5,986
Pretax Margin (Annual)-1231.96%
Cash / Share (Annual)$0.14
3-Month Return Std Dev103.43%
Net Income / Employee (TTM)$-73,700
ROE (Last FY)-60.82%
Net Interest Coverage (Annual)-16.12x
EPS Basic Excl Extra (Annual)$-0.27
Total Debt / Equity (Quarterly)0.07x
EPS Incl Extra (TTM)$-0.27
ROI (TTM)-54.29%
Revenue / Share (Annual)$0.02
Tangible BV / Share (Annual)$0.42
Price vs S&P 500 (52W)-60.50%
Year-to-Date Return-3.37%
5-Day Price Return13.05%
EPS Normalized (Annual)$-0.27
ROA (5Y Avg)-40.37%
Net Profit Margin (Annual)-1227.06%
Month-to-Date Return10.26%
Cash Flow / Share (TTM)$-0.20
EBITD / Share (Annual)$-0.24
Operating Margin (Annual)-1231.95%
LT Debt / Equity (Annual)0.06x
ROI (5Y Avg)-43.76%
LT Debt / Equity (Quarterly)0.06x
EPS Basic Excl Extra (TTM)$-0.27
P/TBV (Quarterly)3.15x
P/B Ratio (Annual)3.09x
Book Value / Share (Annual)$0.43
Price vs S&P 500 (13W)15.78%
Beta-0.16x
Revenue / Share (TTM)$0.02
ROE (TTM)-58.15%
52-Week Low$0.68
gGradeA
mGradeC
vgmGradeB
Show chart for
Analyst Recommendations
Apr 2025
May 2025
Jun 2025
Jul 2025
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GDTCCytoMed Therapeutics Limited Ordinary Shares | — | A | C | $1.29 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
CytoMed Therapeutics is a pre-clinical biopharmaceutical company developing cell-based immunotherapies for cancer treatment using proprietary technologies. The company operates two main segments: the development of innate immune and pluripotent stem cell therapies, and the processing and banking of cells, including cord blood-derived therapies. Based in Singapore and Malaysia, the company generates the majority of its revenue from Malaysia.